Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jourdes Aurélie, Cellerin Elise, Touzeau Cyrille, Harel Stéphanie, Denis Blandine, Escure Guillaume, Faure Emmanuel, Jamard Simon, Danion Francois, Sonntag Cécile, Ader Florence, Karlin Lionel, Soueges Sarah, Cazelles Clarisse, de La Porte des Vaux Clémentine, Frenzel Laurent, Lanternier Fanny, Brousse Xavier, Cazaubiel Titouan, Berger Pierre, Collignon Aude, Blot Mathieu, Pieragostini Andrea, Charles Morgane, Chaleteix Carine, Redor Alexis, Roland Virginie, Cartau Tom, Macro Margaret, Chalopin Thomas, Vallet Nicolas, Perrot Aurore, Martin-Blondel Guillaume, G2I and the IFM networks
Аннотация
METHODS: A retrospective, multicentre study in BsAb-treated patients with multiple myeloma was performed in 14 French centres from December 2020 to February 2023. The primary objective was to describe the incidence of infections that required hospitalization, specific treatment, or adaptation in BsAb administration.
RESULTS: Among 229 patients with multiple myeloma treated with BsAb, 153 (67%) received teclistamab, 47 (20%) received elranatamab, and 29 (13%) talquetamab. We reported a total of 234 infections, including 123 (53%) of grade of ≥3. Predominant infections affected the respiratory tract (n = 116, 50%) followed by bacteraemias (n = 36, 15%). The hospitalization rate was 56% (n = 131), and 20 (9%) infections resulted in death. Global cumulative incidence of the first infection was 70% in all patients, 73% in patients treated with B-cell maturation antigen-targeting, and 51% with GPRC5D-targeting BsAb. In univariate analyses, corticosteroids for cytokine release syndrome (CRS)/immune effector cell-associated neurotoxicity syndrome (ICANS) were associated with a higher risk of first infection (HR = 2.13; 95% CI, 1.38-3.28), whereas GPRC5D-targeting BsAb and anti-bacterial prophylaxis were associated with a lower risk (HR = 0.53; 95% CI, 0.3-0.94 and HR = 0.65; 95% CI, 0.46-0.9). Fine and Gray multivariate model found that only corticosteroids for CRS/ICANS were correlated with a higher risk of first infection (HR = 2.01; 95% CI, 1.27-3.19).
DISCUSSIONS: The implementation of preventive measures that aim to mitigate the risk of infection under BsAb is pivotal, notably in patients who received corticosteroids for CRS/ICANS.